Jennifer M. Loftis, Ph.D. (she/her)

  • Professor of Psychiatry, School of Medicine
  • Professor of Behavioral Neuroscience, School of Medicine
  • Core Faculty, Clinical Psychology Doctoral Program, School of Medicine

Biography

Research

Dr. Jennifer Loftis is a Research Career Scientist at the VA Portland Health Care System and a Professor in the Departments of Psychiatry and Behavioral Neuroscience at OHSU. Her research investigates the neuroimmunological mechanisms contributing to mood disorders and cognitive impairments, discovering treatment targets and testing new interventions for improving neuropsychiatric function. Dr. Loftis’s translational research program uses rodent models and human research participants to characterize inflammatory pathways involved in cognitive dysfunction and neuropsychiatric symptoms, particularly in the context of substance misuse and chronic viral infection. She identified a novel role for cytokines in the development of depressive symptoms in patients with chronic hepatitis C, and this finding has led to the testing of hypotheses regarding how circulating inflammatory cytokines affect central nervous system (CNS) functioning. Dr. Loftis’s long-term goal as a principal investigator is to expand our understanding of the biochemical and molecular mechanisms associated with neuropsychiatric impairments and CNS inflammation.

Teaching/Mentorship

Dr. Loftis is an active mentor and teacher in the community. At OHSU, she is a core faculty member for the Clinical Psychology Ph.D. program and a mentor for the Partnership for Scientific Inquiry program. She also mentors for the VA Mental Illness Research Education Clinical Center of Excellence (MIRECC) and VA Career Development Award program.

Administration/Service

Dr. Loftis balances her research and teaching responsibilities with administrative and community service. At OHSU, she serves on the Department of Behavioral Neuroscience Admissions Committee. At the VA Portland Health Care System, she is chair of the Subcommittee on Research Safety, member of the Research & Development Committee, and alternate member of the Institutional Animal Care and Use Committee.

Education and training

  • Degrees

    • B.A., 1990, University of California at Santa Barbara
    • M.A., 1994, Fairleigh Dickinson University
    • Ph.D., 2002, Oregon Health & Science University
  • Fellowship

    • Post-doctoral fellowship, Molecular Microbiology & Immunology, OHSU, 2004 - 2007

Areas of interest

  • Neuroscience
  • Immunology
  • Cognition
  • Mood disorders
  • Substance use disorders
  • Virology

Publications

Selected publications

  • Loftis JM, Ast HK, Bruton AM, Srikanth P, Ramesh R, Erikson DW, Robinette LM, Hatsu IE, Leung BMY, Machingo TA, Arnold LE, Johnstone JM. Multinutrient Supplementation in Children With ADHD Reduced Pro- and Anti-Inflammatory Immune Factors in the MADDY Randomized Controlled Trial. J Atten Disord. 2026 Jun;30(6):727-746. doi: 10.1177/10870547251397701. Epub 2026 Jan 22. PMID: 41571599; PMCID: PMC12959162.
  • Wood EK, Huang E, Sano ER, Loftis JM. Greater fatigue, disturbed sleep, persistent memory problems, and reduced CD4+ T cell and B cell percentages in adults with a history of methamphetamine dependence. J Neuroimmunol. 2025 May 15;402:578567. doi: 10.1016/j.jneuroim.2025.578567. Epub 2025 Feb 25. PMID: 40088605; PMCID: PMC11974374.
  • Loftis JM. Seeking understanding and action for the neurologic consequences of SARS-CoV-2 infection. Brain Behav Immun. 2024 Feb;116:216-217. doi: 10.1016/j.bbi.2023.12.010. Epub 2023 Dec 7. PMID: 38070622; PMCID: PMC11075524.
  • Loftis JM, Ramani S, Firsick EJ, Hudson R, Le-Cook A, Murnane KS, Vandenbark A, Shirley RL. Immunotherapeutic treatment of inflammation in mice exposed to methamphetamine. Front Psychiatry. 2023 Nov 9;14:1259041. doi: 10.3389/fpsyt.2023.1259041. PMID: 38025429; PMCID: PMC10666795.
  • Loftis JM, Firsick E, Shirley K, Adkins JL, Le-Cook A, Sano E, Hudson R, Moorman J. Inflammatory and mental health sequelae of COVID-19. Compr Psychoneuroendocrinol. 2023 Aug;15:100186. doi: 10.1016/j.cpnec.2023.100186. Epub 2023 May 18. PMID: 37223650; PMCID: PMC10191701.
  • Sandau US, Loftis JM. Toward a better understanding of inflammatory microvesicles in alcohol use disorder. J Neurosci Res. 2021 Oct;99(10):2364-2366. doi: 10.1002/jnr.24930. Epub 2021 Jul 22. PMID: 34292625.
  • Huckans M, Boyd S, Moncrief G, Hantke N, Winters B, Shirley K, Sano E, McCready H, Dennis L, Kohno M, Hoffman W, Loftis JM. Cognition during active methamphetamine use versus remission. J Clin Exp Neuropsychol. 2021 Oct 6:1-12. doi: 10.1080/13803395.2021.1976734. Epub ahead of print. PMID: 34612792.
  • Zaccari B, Callahan ML, Storzbach D, McFarlane N, Hudson R, Loftis JM. Yoga for veterans with PTSD: Cognitive functioning, mental health, and salivary cortisol. Psychol Trauma. 2020 Nov;12(8):913-917. doi: 10.1037/tra0000909. Epub 2020 Aug 10. PMID: 32772534; PMCID: PMC7880235.
  • Gustafsson HC, Sullivan EL, Battison EAJ, Holton KF, Graham AM, Karalunas SL, Fair DA, Loftis JM, Nigg JT. Evaluation of maternal inflammation as a marker of future offspring ADHD symptoms: A prospective investigation. Brain Behav Immun. 2020 Oct;89:350-356. doi: 10.1016/j.bbi.2020.07.019. Epub 2020 Jul 21. PMID: 32707260; PMCID: PMC7703804.
  • Loftis JM, Byrne ML, Measelle J. Special Issue: Contexts and Consequences of Childhood Inflammation. Brain Behav Immun. 2020 May;86:1-3. doi: 10.1016/j.bbi.2019.11.005. Epub 2019 Nov 11. PMID: 31726087; PMCID: PMC7402616.
  • Loftis JM, Navis T, Taylor J, Hudson R, Person U, Lattal KM, Vandenbark AA, Shirley R, Huckans M. Partial MHC/neuroantigen peptide constructs attenuate methamphetamine-seeking and brain chemokine (C-C motif) ligand 2 levels in rats. Eur J Pharmacol. 2020 Aug 5;880:173175. doi: 10.1016/j.ejphar.2020.173175. Epub 2020 May 13. PMID: 32416183; PMCID: PMC7326336.

Publications